Rhinomed

Rhinomed is a global medical device company specializing in wearable nasal technology for respiration, sleep, diagnosis of upper respiratory disease, and nasal drug delivery. The company manufactures diagnostic swabs (Rhinoswab and Rhinoswab Junior) designed for safe, comfortable, and reliable respiratory sample collection for COVID-19, influenza, RSV, and other upper respiratory pathogens. Rhinoswab Junior is specifically engineered for pediatric patients and has been validated in clinical studies demonstrating superior accuracy, comfort, and ease-of-use compared to traditional nasopharyngeal swabs. Beyond diagnostics, Rhinomed develops wearable devices for clinical applications including nasal stenting, breathing assistance for athletes (Turbine—designed to increase airflow up to 38%), and sleep enhancement (Mute—designed to dilate nasal passages to reduce snoring and mouth breathing). The company serves diagnostic laboratories, hospitals, sports medicine, sleep clinics, and government health agencies. Products are deployed globally with significant adoption in Australia and Europe. Rhinomed has secured major purchase orders from government health agencies (e.g., Victorian Department of Health) and distribution partnerships. The company maintains a pipeline of innovation focused on unmet clinical needs in nasal and respiratory health, including nasal drug delivery platforms and clinical stenting applications. Manufacturing and quality standards align with regulatory requirements for medical devices in key markets.